Guangdong Transtek Medical Electronics Co.Ltd(300562) : annual report for 2021
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Pan Weichao, the person in charge of the company, Feng Yongwei, the person in charge of accounting, and Zhou Guihong, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
All directors have attended the meeting of the board of directors to consider this report.
Any forward-looking statements such as future plans in this annual report do not constitute the company’s substantive commitment to any investors and related persons. Investors and related persons should maintain sufficient risk awareness and understand the differences between plans, forecasts and commitments. Please pay attention to investment risks.
Important:
（1） Risk tips for performance decline
1. Due to the multiple drivers of the global epidemic, the intensification of population aging, the improvement of residents’ living standards, the improvement of residents’ health awareness and the favorable government medical policies, the demand for medical and health IOT and digital medical treatment is becoming more and more urgent. In 2021, with the mission of “digital health protection”, the company joined hands with global partners to actively participate in the construction of global digital health service network with innovation and services, and achieved good results. In the face of the complex global economic situation and the downward pressure of the economy, the company closely focuses on the medium and long-term strategic goal of “becoming a world-class health IOT and digital health service provider”, adheres to user-centered, focuses on the core main business, continuously deepens the cooperation with global strategic partners, continues to strengthen the development of new markets and customers, and actively responds to the challenges of market risks and various adverse factors, To ensure the timely delivery of our products and services, the company achieved rapid growth in all product lines and overall sales revenue. During the reporting period, the company achieved an operating revenue of 18210725 million yuan, an increase of 36.23% over the same period last year.
2. During the reporting period, due to the serious shortage of key materials such as global chips and electronic components, the sharp rise in the price of upstream raw materials, the shortage of energy and the sharp decline in global logistics efficiency, the production cost during the reporting period increased significantly compared with the same period of last year, which had a great adverse impact on the profits of the current period.
3. At this stage, the overall scale of the company’s overseas business accounts for a large proportion. The quotation of long-term framework contracts and orders settled in foreign currency is relatively stable and the price adjustment mechanism is insufficient. During the reporting period, the fluctuation of US dollar exchange rate and the appreciation of RMB have a great impact on the profits of the current period. 4. The company focused on the implementation and reform of the new strategy of medical and health IOT and digital health services. In order to build the company’s long-term driving force, the company continued to increase technology and product innovation and R & D in the fields of telemedicine, household medicine, grass-roots medicine and chronic disease management. During the reporting period, the company significantly increased its long-term R & D investment, which was significantly higher than that in the same period of last year.
During the reporting period, the net profit attributable to the shareholders of the parent company was 8.8688 million yuan, a decrease of 87.36% over the same period of the previous year. During the reporting period, the company’s operating performance was under pressure as a whole.
In the future, the company will continue to focus on the strategy of medical and health IOT and digital health services, build a more globally competitive organizational capacity, strive to improve the global supply chain management ability, focus on optimizing the customer and product structure, continuously improve the cost structure, continuously increase long-term R & D and technology investment, improve the competitiveness of products and services, actively improve the overall operation efficiency and promote the improvement of sustainable profitability.
(II) possible risk factors
1. Management risks brought by the rapid development of the company
With the continuous improvement of the company’s scale, research and management capabilities of IOT, the company needs to become a healthy provider of basic assets in the world, including the continuous improvement of the company’s scale and management level of digital logistics, With sensitivity to market demand and technology development trend, and forward-looking layout of the R & D direction of new products, we can ensure the sustainable development and core competitiveness of the enterprise. If the company’s management level can not meet the needs of rapid scale expansion, the organizational model and management system can not be improved in time with the expansion of the company’s scale, and the new products and technologies with market competitiveness outside China can not be distributed in time, which will weaken the company’s market competitiveness, there are management risks caused by rapid scale expansion, and have an adverse impact on the company’s income growth and profitability.
The company will continue to improve the scientific decision-making, management and operation system, build an incentive mechanism for high-performance talents, match it with the development and expansion of the company, effectively reduce or avoid the management risks brought by the rapid development of the company and promote leapfrog development. Accurately grasp the development trend of the industry, realize strategic development through internal innovation and external M & A, master the industry-leading core technology, improve the influence and reputation of products and brands, and ensure the continuous and stable growth of the company’s performance.
2. Market risk
(1) Foreign market risk
The company actively participates in international market competition. Its export business is mainly carried out in economically developed regions such as Europe, the United States, Japan and South Korea, and its business income accounts for a large proportion of the total operating income. If there are major adverse changes in the trade policies and economic situation of major importing countries, and the product price or quality and new product development ability can not meet the needs of customers, resulting in the failure of new business development and even the loss of inherent customers, it will affect the healthy and stable development of overseas business, which is the main risk that the company may face in the overseas market. The company will pay close attention to the international trade policy and economic situation, further improve the added value and comprehensive competitiveness of products, continue to strengthen the expansion of overseas markets, effectively improve the market share of products and enhance the comprehensive profitability of the company.
(2) China market risk
China’s intelligent health and medical products have high innovation requirements and fast update iteration, which puts forward high requirements for the launch efficiency of new products. The more important link to realize users’ demand for health management is the tracking and intervention of professionals on users’ health measurement data, that is, the operation and management of users’ data of intelligent products. At present, the company is actively exploring the business model and profit model of these data operations, but the results are uncertain.
The company will continue to strengthen innovation and R & D, improve the scientific and technological content of products, develop and design more humanized and differentiated products, improve brand awareness, and form its own unique advantages in the market, so as to improve its anti risk ability.
3. The increase of costs and expenses puts pressure on the company’s cost control
The company’s operating costs mainly include raw materials, manufacturing costs, labor costs, etc. if the price of raw materials and labor costs rise sharply, the company cannot effectively control costs and expenses, which will have an adverse impact on the company’s profitability. The company will actively promote lean management and reduce costs in multiple levels and all directions by strengthening cost analysis in all links of the supply chain and optimizing product technology. At the same time, through the optimal allocation of resources and personnel and lean management, improve the efficiency of resource utilization, make full use of their own product advantages, scale advantages and technical advantages, and effectively reduce risks.
4. Exchange rate fluctuation risk
At this stage, the overall scale of the company’s export business is large. In the future, the company will actively explore the high-end market at home and abroad, strengthen cooperation with high-quality customers in the industry, and the scale of overseas business will continue to grow. The fluctuation of foreign exchange rate will affect the company’s pricing and profitability, thus affecting the price competitiveness of the company’s products and bringing certain risks to the company. If there is a major change in China’s exchange rate policy in the future, or there is a significant fluctuation in the exchange rate of RMB in the future, it will affect the exchange gains and losses of the company and have a direct impact on the net profit.
The company will further strengthen the foreign exchange risk management mechanism, pay close attention to exchange rate changes, strengthen the research and prediction of medium and long-term exchange rate trends, pay attention to the foreign exchange business training of relevant business personnel of the company, further increase their knowledge reserves, and provide guarantee for the correct foreign exchange business decisions of the company. At the same time, measures such as optimizing the allocation of foreign currencies, locking the exchange rate by using financial instruments such as long-term foreign exchange settlement, etc. are taken to reduce this risk, fixing the exchange rate in the business contract and starting price negotiation at an appropriate time, so as to effectively control the adverse impact of exchange rate fluctuations on the business operation of the company.
(III) profit distribution plan
The profit distribution plan approved by the board of directors is: take 214701188 shares as the base, distribute cash dividend of 0.10 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance 54 Section V environmental and social responsibility 77 section VI important matters 79 Section VII changes in shares and shareholders Section VIII preferred shares 102 section 9 relevant information of bonds 103 section x financial report one hundred and four
Directory of documents for future reference
1、 The financial statements containing the signatures and seals of the legal representative, the financial principal and the person in charge of the accounting institution of the company. 2、 The original of the audit report with the seal of the accounting firm and the signature and seal of the certified public accountant. 3、 The originals of all company documents and announcements publicly disclosed on the information disclosure media designated by the CSRC during the reporting period. 4、 The company’s 2021 annual report with the signature of the legal representative. 5、 Other relevant information. The place where the above documents for future reference are prepared: the office of the board of directors of the company.
interpretation
Explanatory item refers to the explanatory content
Guangdong Transtek Medical Electronics Co.Ltd(300562) , the company and the company refer to Guangdong Transtek Medical Electronics Co.Ltd(300562)
General meeting of shareholders refers to the general meeting of Guangdong Transtek Medical Electronics Co.Ltd(300562) shareholders
Board of directors refers to Guangdong Transtek Medical Electronics Co.Ltd(300562) board of directors
Board of supervisors refers to Guangdong Transtek Medical Electronics Co.Ltd(300562) board of supervisors
Shenzhen Lexin refers to Shenzhen Guangdong Transtek Medical Electronics Co.Ltd(300562) Electronics Co., Ltd
Chuangyuan sensor refers to Zhongshan Chuangyuan sensor Co., Ltd
Chuangyuan trade refers to Zhongshan Chuangyuan Trade Co., Ltd
Zhongshan Lexin refers to Zhongshan Lexin Electronics Co., Ltd
Zhongshan Leheng refers to Zhongshan Leheng Electronics Co., Ltd
U.S. subsidiary means Mio labs Inc
Hong Kong subsidiary means Hong Kong Chuangyuan Co., Ltd
Ruikang Hongye refers to Shenzhen Ruikang Hongye Technology Development Co., Ltd
Sound source technology refers to sound source technology (Shenzhen) Co., Ltd
Huikang investment refers to Suichuan Huikang Enterprise Management Service Center (limited partnership), which has been renamed Tai’an Huikang Enterprise Management Service Center (limited partnership)
Xierun investment refers to Suichuan xierun Enterprise Management Service Center (limited partnership), which has been renamed Tai’an xierun Enterprise Management Service Center (limited partnership)
The controlling shareholder refers to Mr. Pan Weichao
Actual controller refers to Mr. Pan Weichao
CSRC and CSRC refer to China Securities Regulatory Commission
Shenzhen Stock Exchange and stock exchange refer to Shenzhen Stock Exchange
It refers to an information carrier based on the Internet, traditional telecommunication network, etc., which enables all universal IOT physical objects that can be independently addressed to form an interconnected network.
Chronic disease / chronic disease refers to the general name of diseases that do not constitute infection but have long-term accumulation and form disease morphological damage.
Company Law refers to the company law of the people’s Republic of China
The articles of association refers to the Guangdong Transtek Medical Electronics Co.Ltd(300562) articles of association
Accounting firm and Lixin means Lixin Accounting firm (special general partnership)
Recommendation institution, Haitong Securities Company Limited(600837) refers to Haitong Securities Company Limited(600837)
Yuan, 10000 yuan and 100 million yuan refer to RMB yuan, 10000 yuan and 100 million yuan
The reporting period and the end of the reporting period refer to the period from January 1, 2021 to December 31, 2021
